Karuna Therapeutics

Traded on the St. Petersburg Stock Exchange
Karuna is an American clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. It was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Karuna Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Karuna Therapeutics balance sheet

Report period20182019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Karuna Therapeutics cash flows

Report period20182019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Karuna Therapeutics multipliers

Report period20182019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Karuna Therapeutics profitability

Report period20182019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Karuna Therapeutics assets
Karuna Therapeutics cash flows

Karuna Therapeutics dividend policy

The company doesn't provide dividends

Karuna Therapeutics shares

TickerNameTypeNominal valueISINPrice
KRTX:USKaruna TherapeuticsCommon share-US48576A1007$329.8
Karuna Therapeutics news
05.05.2022
Karuna Therapeutics reported a GAAP loss of $58.218 million for the 3 months of 2022, up 90.9% from $30.497 million the previous year.
Source: {source} pictogram investors.karunatx.com
Pictogram next
24.02.2022
Karuna Therapeutics' GAAP loss for 2021 was $143.805 million, up 2.1 times from $68.554 million in the previous year. Revenue was $36.964 million; the company did not generate revenue last year.
Source: {source} pictogram investors.karunatx.com
Pictogram next
05.08.2021
Karuna Therapeutics' GAAP loss for 6 months of 2021 was $64.913 million, up 2.5 times from $25.704 million in the previous year.
Source: {source} pictogram investors.karunatx.com
Pictogram next
All Karuna Therapeutics news
General information
Company nameKaruna Therapeutics
Tags#pharmacy, #biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address33 Arch Street Suite 3110 Boston, MA 02110 United States
Mailing address33 Arch Street Suite 3110 Boston, MA 02110 United States
Websiteinvestors.karunatx.com
Information disclosurewww.sec.gov